Skip to content
Melo Podcasts Home
CategoriesLanguagesFollowing

Episode · Talking Points

The PRAGUE-25 Study

5 Aug 2026 · 7 min

Play episode WhatsApp Download

Episode notes

Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.

Podcast

Talking Points

TCTMD · Tech & Science · English

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

More from Talking Points All episodes →

  1. 14 Oct 2026 · 6 minNew

    The BHF PROTECT-TAVI Trial

    Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

  2. 16 Sep 2026 · 9 min

    The FAME 3 Trial

    William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.

  3. 2 Sep 2026 · 8 min

    The TRILUMINATE Pivotal Trial

    Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.

  4. 22 Jul 2026 · 9 min

    The BETAMI-DANBLOCK Trial

    How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.

  5. 1 Jul 2026 · 1 hr 33 min

    New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI

    In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

  6. 3 Jun 2026 · 9 min

    The PROCTOR Trial

    Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.

  7. 20 May 2026 · 5 min

    The SELUTION DeNovo Trial

    Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.

  8. 6 May 2026 · 7 min

    The VESALIUS-CV Trial

    Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

Take it with you

The Melo app keeps playing with the screen off, works in the car and on your watch, wakes you to your station, and browses the whole catalogue offline. Free, no ads, no account.

Get it on Google Play